MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Leucine-rich repeat kinase 2(LRRK2)"

  • 2023 International Congress

    monogenic parkinson´s disease in a chilean cohort

    P. Saffie-Awad, D. Texeira, A. Schumacher-Schuh, T. Leal, M. Inca-Martinez, I. Mata, P. Chana-Cuevas (Santiago, Chile)

    Objective: To describe the minimum prevalence and distribution of monogenic forms of PD in a chilean cohort Background: About 3–5% of Parkinson’s disease (PD) patients…
  • 2023 International Congress

    Caveats regarding a family with PD and LRRK2 mutations

    P. Ferreira, A. Ferreira, D. Fitas, S. Moreira, M. Calejo (Senhora da Hora, Portugal)

    Objective: To describe and discuss genetic considerations regarding a kindred with PD cases with similar clinical characteristics, some with identified mutations in the LRRK2 gene…
  • 2023 International Congress

    Caffeine Intake Interacts with Gene Variants in Parkinson’s disease

    E. Tan, Y. Ong, X. Deng, H. Li, D. Heng, K. Narasimhalu, L. Chan, P. Kumar, W. Au, P. Ratnagopal, L. Tan (Singapore, Singapore)

    Objective: We investigate interactions of caffeine intake with PD risk variants and determine PD risk estimates in caffeine-drinkers carrying these variants. Background: Caffeine intake reduces…
  • 2023 International Congress

    Assessment of variation in α-synuclein seed amplification assay results in the PPMI cohort: Association with hyposmia

    A. Siderowf, L. Concha-Marambio, D. Lafontant, R. Alcalay, L. Chahine, T. Faroud, D. Galasko, K. Kieburt, K. Merchant, B. Mollenhauer, K. Poston, J. Seibyl, C. Tanner, T. Simuni, D. Weintraub, A. Videnovic, S. Choi, C. Caspell-Garcia, C. Coffey, M. Frasier, L. Oliveira, S. Hutten, T. Sherer, C. Soto, K. Marek (Philadelphia, USA)

    Objective: To understand molecular heterogeneity among Parkinson’s disease (PD) patients, and controls based on α-synuclein seed amplification assay (SAA) results. Background: α-synuclein seed amplification assay…
  • 2023 International Congress

    Glucocerebrosidase (GCase) activator, Ambroxol, reduces alpha-synuclein serine-129 phosphorylation and oligomers in mutant LRRK2 R1441G mouse brains

    Z. Choi, E. Chang, H. Liu, S. Zhang, Y. Ruan, K. Leung, S. Pang, M. Kung, D. Ramsden, S. Ho, P. Ho (Hong Kong, Hong Kong)

    Objective: To explore whether inducing brain GCase activity by Ambroxol™ (ABX; a brain-penetrant GCase activator) can reduce a-synuclein (αSyn) serine-129 phosphorylation and oligomer accumulation in…
  • 2023 International Congress

    LRRK2 G2019S as a trigger of inflammatory signaling in patient-derived microglia

    K. Badanjak, P. Mulica, M. Tziortziou, S. Delcambre, S. Smajic, C. Venegas, M. Ali, T. Rolova, J. Koistinaho, P. Seibler, S. Cowley, J. Trinh, S. Pereira, P. Antony, E. Glaab, A. Grünewald (Esch-sur-Alzette, Luxembourg)

    Objective: This study explores the inflammatory processes in leucine-rich repeat kinase 2 (LRRK2)- microglia carrying the G2019S mutation and determines their contribution to Parkinson’s disease…
  • 2023 International Congress

    Differential Rab10 & Rab8A phosphorylation by LRRK2 variants G2019S & I1371V manifests differences in membrane fluidity & pathogenicity.

    KH. Singh, IND. Datta (Bengaluru, India)

    Objective: To evaluate the difference in substrate (Rab8A & Rab10) phosphorylation by LRRK2 variants G2019S & I1371V on membrane fluidity & pathogenicity. Background: LRRK2 is…
  • 2023 International Congress

    LRRK2 Inhibition by BIIB122/DNL151 Demonstrates Robust Target and Lysosomal Engagement: Pharmacokinetics, Pharmacodynamics and Safety in Phase 1 and Phase 1b Studies in Healthy and Parkinson’s Participants

    S. Dhuria, P. Roychowdhury, H. Wong, S. Huntwork-Rodriguez, H. Solanoy, M. Goo, R. Maciuca, O. Mabrouk, K. Fraser, K. Scearce-Levie, D. Graham, D. Jennings, M. Troyer (South San Francisco, USA)

    Objective: To characterize the pharmacokinetics (PK), pharmacodynamics, safety, and exposure-response (E-R) relationships of BIIB122/DNL151 to inform on clinical dose selection. Background: Increased LRRK2 kinase activity…
  • 2023 International Congress

    Analysis of α-Synuclein Seed Amplification Assay in Carriers of GBA and LRRK2 Pathogenic Variants

    K. Fraser, A. Mirelman, O. Mabrouk, N. Omer, L. Concha-Marambio, T. Gurevich, A. Bar Shira, M. Gana-Weisz, O. Goldstein, A. Orr-Urtreger, M. Kestenbaum, J. Cedarbaum, T. Dam, J. Shirvan, N. Giladi, D. Graham, R. Alcalay, A. Thaler (Cambridge, USA)

    Objective: To assess α-synuclein seed amplification assay (αS-SAA) in cerebrospinal fluid (CSF) from a cohort of PD patients and non-manifesting carriers (NMCs) of pathogenic GBA…
  • 2023 International Congress

    Radiological markers of CSF α-synuclein aggregation in Parkinson’s disease patients

    A. Droby, A. Yoffe-Vasiliev, K. Fraser, O. Mabrouk, B. Cohen, N. Omer, A. Bar Shira, M. Gana-Weisz, O. Goldstein, R. Alcalay, A. Orr-Urtreger, J. Shirvan, J. Cedarbaum, N. Giladi, A. Mirelman, A. Thaler (Tel-Aviv, Israel)

    Objective: To investigate the association between cerebrospinal (CSF) αS aggregates, MRI, and dopamine transporter spectral tomography (DaTscanTM) imaging metrics. Background: Synuclein amplification assays (SAA) enables…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • #28953 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • VIT-D and Tics Movement Disorder
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley